Description: Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Home Page: clearsidebio.com
900 North Point Parkway
Alpharetta,
GA
30005
United States
Phone:
678 270 3631
Officers
| Name | Title |
|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, CEO & Director |
| Mr. Charles A. Deignan | Chief Financial Officer |
| Ms. Jenny R. Kobin | Head of Investor Relations |
| Mr. Rick McElheny | Senior Vice President of Corporate Development & Alliance Management |
| Mr. Rafael V. Andino | Senior Vice President of Engineering & Manufacturing |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer |
| Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. | Chief Medical Officer |
Exchange: STU
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9681 |
| Price-to-Sales TTM: | 9.9728 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 30 |